Metformin for the Minimization of Geographic Atrophy Progression in Patients With AMD

PHASE2CompletedINTERVENTIONAL
Enrollment

66

Participants

Timeline

Start Date

April 30, 2016

Primary Completion Date

April 30, 2022

Study Completion Date

October 31, 2022

Conditions
Age-Related Macular DegenerationMacular Degeneration, Age-RelatedDry Macular DegenerationGeographic Atrophy
Interventions
DRUG

Metformin

Trial Locations (12)

33907

Retina Health Center, Fort Myers

60611

Northwestern University, Chicago

60612

University of Illinois at Chicago, Chicago

78705

Austin Retina Associates, Austin

93454

California Retina Consultants, Santa Maria

94121

San Francisco Veteran Affairs Medical Center, San Francisco

94143

University of California San Francisco, San Francisco

94304

Palo Alto Veteran Affairs Medical Center, Palo Alto

95403

North Bay Vitreoretinal Consultants, Santa Rosa

95616

University of California, Davis, Davis

95819

Retinal Consultants Medical Group, Sacramento

97239

Oregon Health and Science University, Portland

All Listed Sponsors
collaborator

San Francisco Veterans Affairs Medical Center

FED

collaborator

VA Palo Alto Health Care System

FED

collaborator

University of California, Davis

OTHER

collaborator

University of California, San Diego

OTHER

collaborator

Northwestern University

OTHER

collaborator

University of Illinois at Chicago

OTHER

collaborator

Retinal Consultants Medical Group

OTHER

collaborator

Retina Health Center

INDUSTRY

collaborator

California Retina Consultants

OTHER

collaborator

Oregon Health and Science University

OTHER

lead

University of California, San Francisco

OTHER

NCT02684578 - Metformin for the Minimization of Geographic Atrophy Progression in Patients With AMD | Biotech Hunter | Biotech Hunter